Danhong Injection Alleviates Mechanical Allodynia via Inhibiting ERK1/2 Activation and Elevates BDNF Level in Sciatic Nerve in Diabetic Rat

Qi Wang, Zhuang-Li Guo, Ge-Le Aori, Da-Wei Kong, Wen-Qiang Yang, Li Zhang, and Yan-Bing Yu

1 Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China
2 Department of Neurosurgery, China-Japan Friendship Hospital, Beijing, China
3 Department of Rehabilitation, The Affiliated Hospital of Qingdao University, Qingdao, China

Correspondence should be addressed to Yan-Bing Yu; yuyanbing6666@sina.com

Received 17 October 2017; Revised 1 December 2017; Accepted 4 December 2017; Published 14 January 2018

1. Introduction

Diabetic peripheral neuropathy (DPN) is a major complication of diabetes mellitus (DM) [1]. A third of patients with DPN develop painful symptoms [2]. Painful DPN dramatically impact patients’ quality of life (QoL) compared with painless DPN [3]. However, the current pharmacological treatments are not entirely satisfactory and the side effects are relatively frequent [4]. The pathogenesis of diabetic neuropathic pain is still not clear. Previous studies demonstrated that mitogen-activated protein kinases (MAPKs) including extracellular signal-regulated protein kinase 1/2 (ERK1/2), p38-MAPK (p38), and c-Jun N-terminal kinase (JNK) are correlated with diabetic hyperalgesia in three-week-old diabetic, hyperalgesic rats [5]. Therefore, they may be potential target for diabetic neuropathic pain treatment.

Decreased neurotrophic support is believed to be one of the important mechanisms in the development of DPN [1]. Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family and is critical for the survival and regeneration of neurons in peripheral nervous system. Several studies have reported that the level of BDNF in sciatic nerves decreased significantly in experimental DPN models [6, 7]. Study showed that exogenous BDNF was able to alleviate the impairment of sciatic nerve in young DPN rats [8].

Danhong injection (DHI) is a Chinese Materia Medica standardized product approved by State Food and Drug administration of China (Permission number Z20026866) [9]. The effective constituents are extracted from Radix Salviae miltiorrhizae and Flos Carthami tinctorii [10, 11]. Although it has been widely used in Chinese hospitals and clinics with proven efficacy and safety for the treatment and
Evidence-Based Complementary and Alternative Medicine

prophylaxis of various cardiocerebrovascular diseases [12–14], its therapeutic indications and mechanisms of effects still need to be further discovered.

Recent study has demonstrated that DHI was able to inhibit the development of diabetic retinopathy and nephropathy [15]. In the present study, we tested the effect of DHI on pain syndrome in a rat model of DPN and try to find out the underlining pathways involved in the effect. The effect of DHI on the level of BDNF in sciatic nerve was also evaluated.

2. Materials and Methods

2.1. Animal Experiments. This study was approved by the Committee on the Ethics of Animal Experiments at China-Japan Friendship Hospital. All procedures strictly complied with the Principles of Laboratory Animal Care and the Guide for the Care and Use of Laboratory Animals. Male Sprague-Dawley rats (180–200 g) were purchased from the Beijing HFK Bioscience Co. Ltd. The animals were kept two per cage under a 12-hour light/dark cycle and fed on standard laboratory diet and tap water ad libitum in a temperature- and humidity-controlled room. Rats were acclimatized for 1 week before diabetes was induced by a single injection of STZ (60 mg/kg body weight) intraperitoneally after an overnight fast. Control rat received the same volume of citric acid (60 mg/kg body weight) intraperitoneally. The 4-week treatment started 4 weeks after induction of diabetes. Age- and sex-matched nondiabetic-control rats received the same amount of saline. The blood glucose concentration and body weight were measured at the end of the experiment and mechanical allodynia was measured every two weeks.

In experiment 1, to evaluate the effect of DHI on mechanical allodynia in rats caused by diabetes, diabetic rats were randomly divided into DPN group and DHI treated group. Each group contained 9 rats. Diabetic rats were injected with saline (5 ml/kg body weight, DPN + saline group) or DHI (5 ml/kg body weight, DPN + DHI group) daily intraperitoneally. The 4-week treatment started 4 weeks after induction of diabetes. Age- and sex-matched nondiabetic-control rats received the same amount of saline. The blood glucose concentration and body weight were measured at the end of the experiment and mechanical allodynia was measured every two weeks.

In experiment 2, the role that ERK1/2 plays in the mechanical allodynia was evaluated. 18 rats with 7-week STZ-induced diabetes were used. Mitogen-activated protein kinase (MAPK) kinase 1/2 inhibitor U0126 was delivered intrathecally with a sustained rate of 0.5 μg·μl−1·hr−1 during the 8th week of diabetes. 10% DMSO in artificial CSF (126.6 mM NaCl, 10.0 mM NaHCO3, 2.5 mM KCl, and 2.0 mM MgCl2) was used as vehicle control. The blood glucose concentration, body weight, and mechanical allodynia were measured at the end of the experiment.

2.2. Behavior Study. Rats were placed on stainless steel mesh floor and were acclimatized in individual plexiglass boxes for 30 minutes. The von Frey filaments (range 1.4–26 g, North Coast Medical Inc., CA) were applied perpendicularly to the plantar surface of the hind paw and were bended with a sustained force for 6 s. The presence of brisk withdrawal or paw flinching was regarded as positive response. Every stimulus was applied with an interval of 15 seconds. A total of 3 trials were conducted on every rat with 20 minutes interval. An up and down method was used to calculate 50% paw withdraw threshold [16, 17].

2.3. Intrathecal Infusion. Rats were anaesthetized with sodium pentobarbital (50 mg/kg, i.p.) and immobilized with a stereotactic device. Intrathecal catheters were inserted into subarachnoid spaces through atlantooccipital membrane; the tips were carefully advanced 8 cm caudally to the position of lumbar enlargement. Infusion pumps (Model 1007D, ALZET, flow rate of 1 μl/hr−1) filled with U0126 or vehicle were attached to the end of the catheter and fixed subcutaneously. Incisions were sealed with silk suture. Rats without any neurological deficit were included.

2.4. Tissue Collection. After 8 weeks of diabetes, rats were anaesthetized with sodium pentobarbital and decapitated. Dorsal parts of the lumbar enlargements of the spinal cords and sciatic nerves were collected and snap frozen in liquid nitrogen. Tissues were stored at −80°C before use.

2.5. Western Blot. Lumbar enlargements of the spinal cords (L4–L6) were homogenized with glass homogenizers on ice in lysis buffer (50 mM Tris-HCl, pH = 7.4, 150 mM NaCl, 1% NP-40, 5 mM EDTA) supplemented with protease and phosphatase inhibitor cocktail (Thermo Scientific) and PMSF (Beyotime). The homogenates were then centrifuged at 12000 rpm for 5 minutes at 4°C. The supernatants were collected and protein concentration was determined by BCA assay kit (Beyotime). 20 μg protein was separated by 10% SDS-PAGE and transferred to polyvinylidene fluoride membrane (Thermo Scientific). The membranes were blocked with blocking buffer (Beyotime) and then incubated with rabbit monoclonal antiphosphorylated ERK1/2 antibody (dilution 1:2000, Cell Signaling Technology) overnight at 4°C with shaking. Horseradish peroxidase-conjugated goat anti-rabbit polyclonal antibody (dilution 1:3000, Beyotime) was applied at room temperature for 1 hour. The blots were visualized with enhanced chemiluminescence substrate (Thermo Scientific) in a gel imager (Bio-Rad). For total ERK1/2 detection, membranes were incubated again with rabbit monoclonal anti-ERK1/2 antibody (dilution 1:1000, Cell Signaling Technology) after stripping and blocking. Band density was measured with ImageJ software. Expression of phosphorylated ERK1/2 was corrected for by total ERK1/2 expression from the same sample. Quantitation of the expression of phosphorylated ERK1/2 was represented as fold change compared with control group or vehicle group.

2.6. Real-Time PCR. Total RNA were extracted from spinal cords (L4–L6) using TRIzol reagent (Invivogen) according to manufacturer's protocol. FastQuant RT Kit (TIANGEN) was used for cDNA synthetization. Quantitative PCR reactions were done on Applied Biosystems 7500 with SuperReal Color PreMix reagent (TIANGEN) according to manufacturer's instructions. ΔCT was calculated using the following formula: ΔCT = CTERK1/2 − CTβ-actin. Results were expressed
as fold changes related to control group. Primers for ERK1, ERK2, and β-actin used in the study were as follows:

ERK1; 5'-GGACCTGAAGCCCTCCAATC-3'  
3'-GGGCAAGGCCAAAATCACAG-5'  
ERK2; 5'-AATGTTCTGCACCGTGACCT-3'  
3'-TGGTCTGGATCTGCAACACG-5'  
β-actin; 5'-TACCCCCATTTGACAGCGCAG-3'  
3'-GGACAACACACGCCTGGATGG-5'

2.7. BDNF Assay. Total protein was prepared from sciatic nerves in the way similar with that mentioned in the western blot part. BDNF level was measured by BDNF ELISA kit (Emax Immunoassay System; Promega) according to manufacturer’s instruction and was normalized to protein content that was loaded. Result was expressed as mean percentage of BDNF level found in control rats, which was denoted as 100%.

2.8. Statistical Analysis. All data are presented as mean ± SE. Data analysis was done with SPSS (Version 20.0; IBM Corp, Armonk, NY) software. Normality of data was assessed by 1-sample Kolmogorov-Smirnov test. Data were compared among groups with one-way ANOVA followed by post hoc Bonferroni correction in experiment 1. In experiment 2, data

---

**Figure 1:** Effect of DHI on 50% paw withdraws threshold and ERK1/2 activation in spinal cord after STZ-induced diabetes. DHI or saline treatment was started after 4 weeks of diabetes. (a) Alterations in 50% paw withdraw threshold. (b) Representative western blot result of phosphorylated and total ERK1/2. (c) Phosphorylated ERK1/2 level was first corrected for by total ERK1/2 level and expressed as % control. ∗∗p<0.01 versus control group; #p<0.05 and ##p<0.01 versus control group; Δp<0.05 and p<0.01 versus DPN + saline group. n=8-9.
Table 1: Baseline and final body weights and final blood glucose levels in different groups.

|                    | Body weight (g) | Blood glucose (mmol/l) |
|--------------------|-----------------|------------------------|
|                    | Baseline        | Final                  |
| Control            | 256.25 ± 2.53   | 523.63 ± 5.64          |
| DPN + saline       | 257.22 ± 1.71   | 334.11 ± 7.57**        |
| DPN + DHI          | 258.11 ± 2.02   | 339.90 ± 6.52**        |
| DPN + vehicle      | 258.25 ± 2.26   | 329.75 ± 5.81          |
| DPNI + U0126       | 257.75 ± 1.75   | 320.63 ± 6.32          |

|                    | Final            |
|--------------------|------------------|
| Control            | 6.68 ± 0.13      |
| DPN + saline       | 6.72 ± 0.09      |
| DPN + DHI          | 6.72 ± 0.14      |
| DPN + vehicle      | 6.60 ± 0.13      |
| DPNI + U0126       | 6.48 ± 0.16      |

**p < 0.01 versus control.

were compared with Student’s t-test between the two groups. A p value < 0.05 was considered statistical significant.

3. Results

Table 1 shows the baseline and final body weights and blood glucose levels. In experiment 1, final body weights were significantly higher in control group than in DPN group (p < 0.01) and DHI treated group (p < 0.01); final blood glucose levels were around four times higher in DPN group (p < 0.01) and DHI treated group (p < 0.01) than in control group; no significant difference was found in final body weights and blood glucose levels between DPN group and DHI treated group. In experiment 2, no significant difference was found between DPN + U0126 rats and DPN + vehicle rats in baseline and final body weights and blood glucose levels.

The 50% withdraw thresholds reduced significantly since the 2nd week after STZ injection (p < 0.05). After 4 weeks of DHI treatment, reduction in 50% withdraw threshold was partially reversed (Figure 1(a)). In order to demonstrate possible pathway involved in the effect of DHI treatment on mechanical allodynia in DPN rat, level of total ERK1/2, phosphorylated ERK1/2 in spinal cord was examined. Western blot showed that level of phosphorylated ERK1/2 in spinal cord was increased in DPN rat and DHI treatment was able to reverse the increased level of phosphorylated ERK1/2 (Figures 1(b) and 1(c)). ERK1/2 mRNA levels were also evaluated. Real-time PCR demonstrated that ERK1/2 mRNA levels were not significantly different between groups (Figure 2).

To confirm that the increased phosphorylated ERK1/2 in spinal cord contributes to mechanical allodynia in DPN rat, sustained intrathecal infusion with U0126 was performed to inhibit the phosphorylation process of ERK1/2. After 1 week of U0126 infusion, the level of phosphorylated ERK1/2 in spinal cord of DPN rat was significantly reduced. The mechanical allodynia was also alleviated in DPN + U0126 group significantly compared with DPN + vehicle group (p < 0.01) (Figure 3).

The BDNF level in sciatic nerve in each group was expressed as fold change related to control group. BDNF decreased significantly in DPN group compared with control group (p < 0.01), and DHI treatment elevated BDNF level significantly compared with saline (p < 0.01) (Figure 4). Additionally, there was no significant difference between DPNI + U0126 treated group and DPN + vehicle group in experiment 2 (data not shown).

4. Discussions

DHI was initially developed to treat various cardiocerebrovascular diseases according to traditional Chinese medicinal theory [18–20]. In present study, we proved that DHI alleviated mechanical allodynia through inhibiting the activation of ERK1/2 pathway in spinal cord and elevated the level of BDNF in sciatic nerves in DPN rats.

Mechanical allodynia is a common neuropathic pain syndrome of DPN patients. In this STZ-induced DPN rat model, mechanical allodynia was observed 2 weeks after STZ injection as previously described [21]. ERK1/2 is a member of mitogen-activated protein kinase (MAPK) family and is activated by phosphorylation. Activation of ERK1/2 in spinal cord was thought to play a role in the generation of neuropathic pain in DPN rats [21, 22]. Meanwhile some others argued that diabetes-induced activation of ERK1/2 is a protective reaction of stressed nerve cells [23, 24]. In this study, we found 2 weeks of DHI treatment ameliorated the mechanical allodynia and the effect was accompanied...
by reduced activation of ERK 1/2 in spinal cord. We further confirmed that reduced activation of ERK1/2 resulted in the alleviation of mechanical allodynia by continuous intrathecal injection of specific ERK1/2 inhibitor. Therefore, treatment effect of DHI on mechanical allodynia could be or, at least in part, attributed to the inhibitory property on ERK1/2 activation.

Loss of neurotrophic support is believed to involve in the pathogenesis of DPN. Several clinical trials have tried to supply DPN patients with recombinant human NGF or BDNF to study their effects on neuropathic deficits caused by DPN. But they both failed to achieve positive effects [25, 26]. It is believed that systemic administration of NGF or BDNF might not achieve its local, sufficient, and sustained effects [7, 27]. Additionally high rate of the presence of hyperalgesia at injection site is also a troublesome issue [25]. Thus, medications which could raise the level of endogenous neurotrophic factors may be ideal therapies [7, 27]. In the present study, we proved that DHI increased BDNF level in sciatic nerve of DPN rats. Further studies may be conducted to evaluate the role of DHI as an endogenous BDNF stimulator.

**Figure 3:** Effect of intrathecal U0126 infusion on mechanical allodynia caused by DPN and confirmation of the inhibition of ERK1/2 activation in spinal cord by intrathecal U0126 injection. (a) 50% paw withdraw thresholds in vehicle and U0126 treated groups. (b) Representative western blot result of p-ERK1/2 and t-ERK1/2. (c) Phosphorylated ERK1/2 level was first corrected for by total ERK1/2 level and expressed as % DPN + vehicle. **P < 0.01 versus DPN + vehicle. n = 8.
examined. BDNF in sciatic nerves of DPN rats. Other inhibitors maybe of ERK1/2 inhibitor was found unable to influence the level of pathways involved. In the present study, intrathecal injection catheters may be a suitable method to find out possible Sustained delivery of various inhibitors through intrathecal induced reduction of neurotrophic factors in sciatic nerve. ies may be preferred to elucidate the mechanisms of DPN- ticking therealdiseaseconditionsinvivo.Futureinvivostud- turedSchwanncellsmaynotbeanappropriatemodelmim- condition, were reported [28–31]. Therefore, high glucose decreased, unchanged, and increased expression of neurotrophic factors by Schwann cells exposed to high glucose culture medium to achieve an in vitro studies. In most of these studies, Schwann cells were exposed to high glucose culture medium to achieve an experimental DPN model. However, heterogeneous results,南海台风路径和强度推测。Sorkhkamanzadeh, and A. Sheikhy, "Does endurance training compensate for neurotrophin deficiency following diabetic neuropathy?" Iranian Red Crescent Medical Journal, vol. 18, no. 10, Article ID e37757, 2016.

5. Conclusions

ERK1/2 activation in spinal cord contributes to mechanical allodynia in STZ-induced DPN rat. DHI alleviates the mechanical allodynia by the inhibition of ERK1/2 activation. In addition, DHI treatment reverses the reduction of BDNF in sciatic nerve in DPN rat. This study extends the potential indication for DHI which has been conventionally used for cardiocerebrovascular diseases.

Conflicts of Interest

All authors ensure that there is no competing financial interest.

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (Grants nos. 81173424, 81373796, and 81673793).

References

[1] A. M. Vincent, B. C. Callaghan, A. L. Smith, and E. L. Feldman, "Diabetic neuropathy: cellular mechanisms as therapeutic targets," Nature Reviews Neurology, vol. 7, no. 10, pp. 573–583, 2011.
[2] S. Tesfaye and D. Selvarajah, "Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy," Diabetes/Metabolism Research and Reviews, vol. 28, no. 1, pp. 8–14, 2012.
[3] A. Peltier, S. A. Goutman, and B. C. Callaghan, "Painful diabetic neuropathy," British Medical Journal, vol. 348, Article ID g1799, 2014.
[4] S. Tesfaye, A. J. M. Boulton, and A. H. Dickenson, "Mechanisms and management of diabetic painful distal symmetrical polyneuropathy," Diabetes Care, vol. 36, no. 9, pp. 2456–2465, 2013.
[5] L. Daulhac, C. Mallet, C. Courteix et al., "Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate- dependent mechanisms," Molecular Pharmacology, vol. 70, no. 4, pp. 1246–1254, 2006.
[6] R. Li, J. Zhang, L. Zhang, Q. Cui, and H. Liu, "Angelia injection promotes peripheral nerve structure and function recovery with increased expressions of nerve growth factor and brain derived neurotrophic factor in diabetic rats," Current Neurovascular Research, vol. 7, no. 3, pp. 213–222, 2010.
[7] R. Eslami, R. Gharakhanlou, A. Kazemi, A. B. Dakhili, G. Sorkhkamanzadeh, and A. Sheikhy, "Does endurance training compensate for neurotrophin deficiency following diabetic neuropathy?" Iranian Red Crescent Medical Journal, vol. 18, no. 10, Article ID e37757, 2016.
[8] M. A. Cotter, A. Love, and N. E. Cameron, "Effects of neurotrophins on nerve function and regeneration in young diabetic rats," Diabetics, vol. 46, p. 126, 1997.
[9] X. Yang, J. Orgah, D. Wang et al., "Danhong injection reduces vascular remodeling and up-regulates the Kallikrein-kinin system in spontaneously hypertensive rats," Scientific Reports, vol. 7, no. 1, 2017.
[10] Q.-Q. Zhang, X. Dong, X.-G. Liu, W. Gao, P. Li, and H. Yang, "Rapid separation and identification of multiple constituents in Danhong Injection by ultra-high performance liquid chromatography coupled to electrospray ionization quadrupole time-of-flight tandem mass spectrometry," Chinese Journal of Natural Medicines, vol. 14, no. 2, pp. 147–160, 2016.
[11] H.-T. Liu, Y.-F. Wang, O. Olaleye et al., "Characterization of in vivo antioxidant constituents and dual-standard quality assessment of Danhong injection," Biomedical Chromatography, vol. 27, no. 5, pp. 653–663, 2013.
[12] C.-X. Li, J.-F. Tang, F. Meng, and X.-L. Li, "Security revaluation study based on nested case-control method of danhong injection," China Journal of Chinese Materia Medica, vol. 37, no. 18, pp. 2735–2738, 2012.
[13] J. Du, W. Yang, D. Yi, Y. Xie, Y. Zhuang, and Q. Chen, "Analysis of using Danhong injection to treatment coronary heart disease patient’s medicines based on real world HIS database," China
Evidence-Based Complementary and Alternative Medicine

Journal of Chinese Materia Medica, vol. 36, no. 20, pp. 2821–2824, 2011.

[14] J. R. Wu, X. M. Zhang, and B. Zhang, "Danhong injection in the treatment of acute coronary syndrome: a systematic review and meta-analysis," American Journal of Chinese Medicine, vol. 43, no. 2, pp. 199–214, 2015.

[15] M. Liu, Q. Pan, Y. Chen et al., "Administration of Danhong Injection to diabetic db/db mice inhibits the development of diabetic retinopathy and nephropathy," Scientific Reports, vol. 5, article 11219, 2015.

[16] W. J. Dixon, "Efficient analysis of experimental observations," Annual Review of Pharmacology and Toxicology, vol. 20, pp. 441–462, 1980.

[17] S. R. Chaplan, F. W. Bach, J. W. Pogrel, J. M. Chung, and T. L. Yaksh, "Quantitative assessment of tactile allodynia in the rat paw," Journal of Neuroscience Methods, vol. 53, no. 1, pp. 55–63, 1994.

[18] H.-P. Mao, X.-Y. Wang, Y.-H. Gao et al., "Danhong injection attenuates isoproterenol-induced cardiac hypertrophy by regulating p38 and NF-κb pathway," Journal of Ethnopharmacology, vol. 186, pp. 20–29, 2016.

[19] Z. Wang, F. Song, J. Li et al., "PET demonstrates functional recovery after treatment by danhong injection in a rat model of cerebral ischemic-reperfusion injury," Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 430757, 9 pages, 2014.

[20] M. Yang, J. Orgah, J. Zhu et al., "Danhong injection attenuates cardiac injury induced by ischemic and reperfused neuronal cells through regulating arginine vasopressin expression and secretion," Brain Research, vol. 1642, pp. 516–523, 2016.

[21] A. Ciruela, A. K. Dixon, S. Bramwell, M. I. Gonzalez, R. D. Pinnock, and K. Lee, "Identification of MEK1 as a novel target for the treatment of neuropathic pain," British Journal of Pharmacology, vol. 138, no. 5, pp. 751–756, 2003.

[22] L. Daulhac, V. Maffre, C. Mallet et al., "Phosphorylation of spinal N-methyl-d-aspartate receptor NRI subunits by extracellular signal-regulated kinase in dorsal horn neurons and microglia contributes to diabetes-induced painful neuropathy," European Journal of Pain, vol. 15, no. 2, pp. 169–e12, 2011.

[23] T. Purves, A. Middlemas, S. Agthong et al., "A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy," The FASEB Journal, vol. 15, no. 13, pp. 2508–2514, 2001.

[24] C. G. Jolivalt, M. Fineman, C. F. Deacon, R. D. Carr, and N. A. Calcott, "GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice," Diabetes, Obesity and Metabolism, vol. 13, no. 11, pp. 990–1000, 2011.

[25] S. C. Apfel, S. Schwartz, B. T. Adornato et al., "Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial," Journal of the American Medical Association, vol. 284, no. 17, pp. 2215–2221, 2000.

[26] A. Wellmer, V. P. Misra, M. K. Sharief, P. G. Kopelman, and P. Anand, "A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy," Journal of the Peripheral Nervous System, vol. 6, no. 4, pp. 204–210, 2001.

[27] N. Hernandez-Pedro, V. Granados-Soto, G. Ordonez et al., "Vitamin A increases nerve growth factor and retinoic acid receptor beta and improves diabetic neuropathy in rats," Translational Research, vol. 164, no. 3, pp. 196–201, 2014.

[28] T. Suzuki, H. Sekido, N. Kato, Y. Nakayama, and C. Yabean-Nishimura, "Neurotrophin-3-induced production of nerve growth factor is suppressed in Schwann cells exposed to high glucose: involvement of the polyol pathway," Journal of Neurochemistry, vol. 91, no. 6, pp. 1430–1438, 2004.

[29] T. Tosaki, H. Kamiya, Y. Yasuda et al., "Reduced NGF secretion by Schwann cells under the high glucose condition decreases neurite outgrowth of DRG neurons," Experimental Neurology, vol. 213, no. 2, pp. 381–387, 2008.

[30] Y.-K. Zhou, Z. Liang, Y. Guo, H.-T. Zhang, and K.-H. Wang, "High glucose upregulates CYP24A1 expression which attenuates the ability of 1,25(OH)2D3 to increase NGF secretion in a rat Schwann cell line RSC96," Molecular and Cellular Endocrinology, vol. 404, pp. 75–81, 2015.

[31] H. Zhu, W.-J. Yu, Y. Le et al., "High glucose levels increase the expression of neurotrophic factors associated with p-p42/p44 MAPK in Schwann cells in vitro," Molecular Medicine Reports, vol. 6, no. 1, pp. 179–184, 2012.